The impact of neuroimmune changes on development of amyloid pathology; relevance to Alzheimer's disease

Immunology

Volumn 141, Issue 3, 2014, Pages 292-301

  Lynch, Marina A ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Alzheimer's disease; Inflammation; Macrophages monocytes; Neuroimmunology

Indexed keywords

AMYLOID; ANTIINFLAMMATORY AGENT; APOLIPOPROTEIN E; CD200 ANTIGEN; CD200 RECEPTOR; CD4 ANTIGEN; CELL SURFACE MARKER; CHEMOKINE RECEPTOR CX3CR1; CRYOPYRIN; FRACTALKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 1; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RANTES; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; ANTIGEN PRESENTING CELL; BLOOD BRAIN BARRIER; BRAIN; BRAIN INFECTION; CELL ACTIVATION; CELL INFILTRATION; CELL POPULATION; COCULTURE; COMPLEMENT ACTIVATION; DISEASE COURSE; DOWN REGULATION; HEMATOPOIETIC CELL; HUMAN; IMMUNE RESPONSE; MACROPHAGE; MICROGLIA; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TH1 CELL; TH2 CELL; UPREGULATION;

ALZHEIMER'S DISEASE; INFLAMMATION; MACROPHAGES/MONOCYTES; NEUROIMMUNOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN; CELL COMMUNICATION; DISEASE PROGRESSION; HUMANS; INTERFERON-GAMMA; MICROGLIA; PHENOTYPE; PROGNOSIS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 84893541699     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12156     Document Type: Review

References (134)

1. McGeer PL, Itagaki S, Tago H, McGeer EG. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci Lett 1987; 79:195-200.
2. Guillot-Sestier MV, Town T. Innate immunity in Alzheimer's disease: a complex affair. CNS Neurol Disord Drug Targets 2013; 20:593-607.
3. Akiyama H, Barger S, Barnum S et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000; 21:383-421.
4. Rubio-Perez JM, Morillas-Ruiz JM. A review: inflammatory process in Alzheimer's disease, role of cytokines. Scientific World Journal 2012; 2012:756357.
5. Solito E, Sastre M. Microglia function in Alzheimer's disease. Front Pharmacol 2012; 3:14.
6. Launer L. Nonsteroidal anti-inflammatory drug use and the risk for Alzheimer's disease: dissecting the epidemiological evidence. Drugs 2003; 63:731-9.
7. Rich JB, Rasmusson DX, Folstein MF, Carson KA, Kawas C, Brandt J. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 1995; 45:51-5.
8. Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997; 48:626-32.
9. Aisen PS, Schafer KA, Grundman M et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003; 289:2819-26.
10. Reines SA, Block GA, Morris JC et al. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 2004; 62:66-71.
11. Imbimbo BP, Solfrizzi V, Panza F. Are NSAIDs useful to treat Alzheimer's disease or mild cognitive impairment? Front Aging Neurosci 2010; 2:19.
12. Parachikova A, Agadjanyan MG, Cribbs DH, Blurton-Jones M, Perreau V, Rogers J et al. Inflammatory changes parallel the early stages of Alzheimer disease. Neurobiol Aging 2007; 28:1821-33.
13. Breitner JC, Haneuse SJ, Walker R, Dublin S, Crane PK, Gray SL, Larson EB. Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort. Neurology 2009; 72:1899-905.
14. Mackenzie IR. Postmortem studies of the effect of anti-inflammatory drugs on Alzheimer-type pathology and associated inflammation. Neurobiol Aging 2001; 22:819-22.
15. Halliday GM, Shepherd CE, McCann H, Reid WG, Grayson DA, Broe GA, Kril JJ. Effect of anti-inflammatory medications on neuropathological findings in Alzheimer disease. Arch Neurol 2000; 57:831-6.
16. Ginhoux F, Greter M, Leboeuf M et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 2010; 330:841-5.
17. Lucin KM, Wyss-Coray T. Immune activation in brain aging and neurodegeneration: too much or too little? Neuron 2009; 64:110-22.
18. Pocock JM, Kettenmann H. Neurotransmitter receptors on microglia. Trends Neurosci 2007; 30:527-35.
19. Savage CD, Lopez-Castejon G, Denes A, Brough D. NLRP3-inflammasome activating DAMPs stimulate an inflammatory response in glia in the absence of priming which contributes to brain inflammation after injury. Front Immunol 2012; 3:288.
20. Honjo K, van Reekum R, Verhoeff NP. Alzheimer's disease and infection: do infectious agents contribute to progression of Alzheimer's disease? Alzheimers Dement 2009; 5:348-60.
21. Holmes C, El-Okl M, Williams AL, Cunningham C, Wilcockson D, Perry VH. Systemic infection, interleukin 1β, and cognitive decline in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2003; 74:788-9.
22. Holmes C, Cunningham C, Zotova E, Woolford J, Dean C, Kerr S, Culliford D, Perry VH. Systemic inflammation and disease progression in Alzheimer disease. Neurology 2009; 73:768-74.
23. Hammond CJ, Hallock LR, Howanski RJ, Appelt DM, Little CS, Balin BJ. Immunohistological detection of Chlamydia pneumoniae in the Alzheimer's disease brain. BMC Neurosci 2010; 11:121.
24. Little CS, Hammond CJ, MacIntyre A, Balin BJ, Appelt DM. Chlamydia pneumoniae induces Alzheimer-like amyloid plaques in brains of BALB/c mice. Neurobiol Aging 2004; 25:419-29.
25. Krstic D, Madhusudan A, Doehner J et al. Systemic immune challenges trigger and drive Alzheimer-like neuropathology in mice. J Neuroinflammation 2012; 9:151.
26. Sheng JG, Bora SH, Xu G, Borchelt DR, Price DL, Koliatsos VE. Lipopolysaccharide-induced-neuroinflammation increases intracellular accumulation of amyloid precursor protein and amyloid β peptide in APPswe transgenic mice. Neurobiol Dis 2003; 14:133-45.
27. Kitazawa M, Oddo S, Yamasaki TR, Green KN, LaFerla FM. Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J Neurosci 2005; 25:8843-53.
28. Wozniak MA, Mee AP, Itzhaki RF. Herpes simplex virus type 1 DNA is located within Alzheimer's disease amyloid plaques. J Pathol 2009; 217:131-8.
29. Itzhaki RF, Lin WR, Shang D, Wilcock GK, Faragher B, Jamieson GA. Herpes simplex virus type 1 in brain and risk of Alzheimer's disease. Lancet 1997; 349:241-4.
30. Carnevale D, De Simone R, Minghetti L. Microglia-neuron interaction in inflammatory and degenerative diseases: role of cholinergic and noradrenergic systems. CNS Neurol Disord Drug Targets 2007; 6:388-97.
31. Neumann H. Control of glial immune function by neurons. Glia 2001; 36:191-9.
32. Lacmann A, Hess D, Gohla G, Roussa E, Krieglstein K. Activity-dependent release of transforming growth factor-β in a neuronal network in vitro. Neuroscience 2007; 150:647-57.
33. Fernandez AM, Fernandez S, Carrero P, Garcia-Garcia M, Torres-Aleman I. Calcineurin in reactive astrocytes plays a key role in the interplay between proinflammatory and anti-inflammatory signals. J Neurosci 2007; 27:8745-56.
34. Wright GJ, Cherwinski H, Foster-Cuevas M et al. Characterization of the CD200 receptor family in mice and humans and their interactions with CD200. J Immunol 2003; 171:3034-46.
35. Wright GJ, Puklavec MJ, Willis AC, Hoek RM, Sedgwick JD, Brown MH, Barclay AN. Lymphoid/neuronal cell surface OX2 glycoprotein recognizes a novel receptor on macrophages implicated in the control of their function. Immunity 2000; 13:233-42.
36. Lyons A, McQuillan K, Deighan BF et al. Decreased neuronal CD200 expression in IL-4-deficient mice results in increased neuroinflammation in response to lipopolysaccharide. Brain Behav Immun 2009; 23:1020-7.
37. Lyons A, Downer EJ, Crotty S, Nolan YM, Mills KH, Lynch MA. CD200 ligand receptor interaction modulates microglial activation in vivo and in vitro: a role for IL-4. J Neurosci 2007; 27:8309-13.
38. Hoek RM, Ruuls SR, Murphy CA et al. Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science 2000; 290:1768-71.
39. Wang XJ, Ye M, Zhang YH, Chen SD. CD200-CD200R regulation of microglia activation in the pathogenesis of Parkinson's disease. J Neuroimmune Pharmacol 2007; 2:259-64.
40. Broderick C, Hoek RM, Forrester JV, Liversidge J, Sedgwick JD, Dick AD. Constitutive retinal CD200 expression regulates resident microglia and activation state of inflammatory cells during experimental autoimmune uveoretinitis. Am J Pathol 2002; 161:1669-77.
41. Lyons A, McQuillan K, Deighan BF et al. Decreased neuronal CD200 expression in IL-4-deficient mice results in increased neuroinflammation in response to lipopolysaccharide. Brain Behav Immun 2009; 23:1020-7.
42. Lyons A, Downer EJ, Costello DA, Murphy N, Lynch MA. Dok2 mediates the CD200Fc attenuation of Aβ-induced changes in glia. J Neuroinflammation 2012; 9:107.
43. Cox FF, Carney D, Miller AM, Lynch MA. CD200 fusion protein decreases microglial activation in the hippocampus of aged rats. Brain Behav Immun 2012; 26:789-96.
44. Liu Y, Bando Y, Vargas-Lowy D, Elyaman W, Khoury SJ, Huang T, Reif K, Chitnis T. CD200R1 agonist attenuates mechanisms of chronic disease in a murine model of multiple sclerosis. J Neurosci 2010; 30:2025-38.
45. Gorczynski RM, Chen Z, Lee L, Yu K, Hu J. Anti-CD200R ameliorates collagen-induced arthritis in mice. Clin Immunol 2002; 104:256-64.
46. Gorczynski RM, Chen Z, Yu K, Hu J. CD200 immunoadhesin suppresses collagen-induced arthritis in mice. Clin Immunol 2001; 101:328-34.
47. Walker DG, Dalsing-Hernandez JE, Campbell NA, Lue LF. Decreased expression of CD200 and CD200 receptor in Alzheimer's disease: a potential mechanism leading to chronic inflammation. Exp Neurol 2009; 215:5-19.
48. Koning N, Bo L, Hoek RM, Huitinga I. Downregulation of macrophage inhibitory molecules in multiple sclerosis lesions. Ann Neurol 2007; 62:504-14.
49. Koning N, Swaab DF, Hoek RM, Huitinga I. Distribution of the immune inhibitory molecules CD200 and CD200R in the normal central nervous system and multiple sclerosis lesions suggests neuron-glia and glia-glia interactions. J Neuropathol Exp Neurol 2009; 68:159-67.
50. Luo XG, Zhang JJ, Zhang CD, Liu R, Zheng L, Wang XJ, Chen SD, Ding JQ. Altered regulation of CD200 receptor in monocyte-derived macrophages from individuals with Parkinson's disease. Neurochem Res 2010; 35:540-7.
51. Lyons A, Lynch AM, Downer EJ, Hanley R, O'Sullivan JB, Smith A, Lynch MA. Fractalkine-induced activation of the phosphatidylinositol-3 kinase pathway attentuates microglial activation in vivo and in vitro. J Neurochem 2009; 110:1547-56.
52. Wolf Y, Yona S, Kim KW, Jung S. Microglia, seen from the CX3CR1 angle. Front Cell Neurosci 2013; 7:26.
53. Lee S, Varvel NH, Konerth ME, Xu G, Cardona AE, Ransohoff RM, Lamb BT. CX3CR1 deficiency alters microglial activation and reduces β-amyloid deposition in two Alzheimer's disease mouse models. Am J Pathol 2010; 177:2549-62.
54. Cho SH, Sun B, Zhou Y, Kauppinen TM, Halabisky B, Wes P, Ransohoff RM, Gan L. CX3CR1 protein signaling modulates microglial activation and protects against plaque-independent cognitive deficits in a mouse model of Alzheimer disease. J Biol Chem 2011; 286:32713-22.
55. Biber K, Neumann H, Inoue K, Boddeke HW. Neuronal 'On' and 'Off' signals control microglia. Trends Neurosci 2007; 30:596-602.
56. Adams S, van der Laan LJ, Vernon-Wilson E, Renardel de Lavalette C, Dopp EA, Dijkstra CD, Simmons DL, van den Berg TK. Signal-regulatory protein is selectively expressed by myeloid and neuronal cells. J Immunol 1998; 161:1853-9.
57. Reinhold MI, Lindberg FP, Plas D, Reynolds S, Peters MG, Brown EJ. In vivo expression of alternatively spliced forms of integrin-associated protein (CD47). J Cell Sci 1995; 108(Pt 11):3419-25.
58. van Beek EM, Cochrane F, Barclay AN, van den Berg TK. Signal regulatory proteins in the immune system. J Immunol 2005; 175:7781-7.
59. Mott RT, Ait-Ghezala G, Town T et al. Neuronal expression of CD22: novel mechanism for inhibiting microglial proinflammatory cytokine production. Glia 2004; 46:369-79.
60. Lyons A, Griffin RJ, Costelloe CE, Clarke RM, Lynch MA. IL-4 attenuates the neuroinflammation induced by amyloid-β in vivo and in vitro. J Neurochem 2007; 101:771-81.
61. Clarke RM, Lyons A, O'Connell F, Deighan BF, Barry CE, Anyakoha NG, Nicolaou A, Lynch MA. A pivotal role for interleukin-4 in atorvastatin-associated neuroprotection in rat brain. J Biol Chem 2008; 283:1808-17.
62. Cox FF, Berezin V, Bock E, Lynch MA. The neural cell adhesion molecule-derived peptide, FGL, attenuates lipopolysaccharide-induced changes in glia in a CD200-dependent manner. Neuroscience 2013; 235:141-8.
63. Eng LF, Ghirnikar RS, Lee YL. Glial fibrillary acidic protein: GFAP - thirty-one years (1969-2000). Neurochem Res 2000; 25:1439-51.
64. Min KJ, Yang MS, Kim SU, Jou I, Joe EH. Astrocytes induce hemeoxygenase-1 expression in microglia: a feasible mechanism for preventing excessive brain inflammation. J Neurosci 2006; 26:1880-7.
65. Lee M, Schwab C, McGeer PL. Astrocytes are GABAergic cells that modulate microglial activity. Glia 2011; 59:152-65.
66. Pascual O, Ben Achour S, Rostaing P, Triller A, Bessis A. Microglia activation triggers astrocyte-mediated modulation of excitatory neurotransmission. Proc Natl Acad Sci U S A 2012; 109:E197-205.
67. von Bernhardi R, Ramirez G. Microglia-astrocyte interaction in Alzheimer's disease: friends or foes for the nervous system? Biol Res 2001; 34:123-8.
68. Aloisi F, De Simone R, Columba-Cabezas S, Penna G, Adorini L. Functional maturation of adult mouse resting microglia into an APC is promoted by granulocyte-macrophage colony-stimulating factor and interaction with Th1 cells. J Immunol 2000; 164:1705-12.
69. Seguin R, Biernacki K, Prat A et al. Differential effects of Th1 and Th2 lymphocyte supernatants on human microglia. Glia 2003; 42:36-45.
70. McQuillan K, Lynch MA, Mills KH. Activation of mixed glia by Aβ-specific Th1 and Th17 cells and its regulation by Th2 cells. Brain Behav Immun 2010; 24:598-607.
71. Murphy AC, Lalor SJ, Lynch MA, Mills KH. Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis. Brain Behav Immun 2010; 24:641-51.
72. Wolf SA, Gimsa U, Bechmann I, Nitsch R. Differential expression of costimulatory molecules B7-1 and B7-2 on microglial cells induced by Th1 and Th2 cells in organotypic brain tissue. Glia 2001; 36:414-20.
73. Townsend KP, Town T, Mori T et al. CD40 signaling regulates innate and adaptive activation of microglia in response to amyloid β-peptide. Eur J Immunol 2005; 35:901-10.
74. Browne TC, McQuillan K, McManus RM, O'Reilly JA, Mills KH, Lynch MA. IFN-γ production by amyloid β-specific Th1 cells promotes microglial activation and increases plaque burden in a mouse model of Alzheimer's disease. J Immunol 2013; 190:2241-51.
75. Cao C, Arendash GW, Dickson A, Mamcarz MB, Lin X, Ethell DW. Aβ-specific Th2 cells provide cognitive and pathological benefits to Alzheimer's mice without infiltrating the CNS. Neurobiol Dis 2009; 34:63-70.
76. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003; 3:23-35.
77. Stein M, Keshav S, Harris N, Gordon S. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med 1992; 176:287-92.
78. Mosser DM. The many faces of macrophage activation. J Leukoc Biol 2003; 73:209-12.
79. Colton CA, Mott RT, Sharpe H, Xu Q, Van Nostrand WE, Vitek MP. Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD. J Neuroinflammation 2006; 3:27.
80. Moore ME, Piazza A, McCartney Y, Lynch MA. Evidence that vitamin D3 reverses age-related inflammatory changes in the rat hippocampus. Biochem Soc Trans 2005; 33:573-7.
81. Colton CA, Wilcock DM. Assessing activation states in microglia. CNS Neurol Disord Drug Targets 2010; 9:174-91.
82. Maher FO, Clarke RM, Kelly A, Nally RE, Lynch MA. Interaction between interferon γ and insulin-like growth factor-1 in hippocampus impacts on the ability of rats to sustain long-term potentiation. J Neurochem 2006; 96:1560-71.
83. Downer EJ, Cowley TR, Cox F, Maher FO, Berezin V, Bock E, Lynch MA. A synthetic NCAM-derived mimetic peptide, FGL, exerts anti-inflammatory properties via IGF-1 and interferon-γ modulation. J Neurochem 2009; 109:1516-25.
84. Kim HS, Whang SY, Woo MS, Park JS, Kim WK, Han IO. Sodium butyrate suppresses interferon-γ-, but not lipopolysaccharide-mediated induction of nitric oxide and tumor necrosis factor-α in microglia. J Neuroimmunol 2004; 151:85-93.
85. Chhor V, Le CT, Lebon S et al. Characterization of phenotype markers and neuronotoxic potential of polarised primary microglia in vitro. Brain Behav Immun 2013; 32:70-85.
86. Chawla A. Control of macrophage activation and function by PPARs. Circ Res 2010; 106:1559-69.
87. Mandrekar-Colucci S, Karlo JC, Landreth GE. Mechanisms underlying the rapid peroxisome proliferator-activated receptor-γ-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease. J Neurosci 2012; 32:10117-28.
88. Choi SH, Aid S, Kim HW, Jackson SH, Bosetti F. Inhibition of NADPH oxidase promotes alternative and anti-inflammatory microglial activation during neuroinflammation. J Neurochem 2012; 120:292-301.
89. Heneka MT, Kummer MP, Stutz A et al. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature 2013; 493:674-8.
90. Wu M, Nissen JC, Chen EI, Tsirka SE. Tuftsin promotes an anti-inflammatory switch and attenuates symptoms in experimental autoimmune encephalomyelitis. PLoS ONE 2012; 7:e34933.
91. Salemi J, Obregon DF, Cobb A, Reed S, Sadic E, Jin J et al. Flipping the switches: CD40 and CD45 modulation of microglial activation states in HIV associated dementia (HAD). Mol Neurodegener 2011; 6:3.
92. Jimenez S, Baglietto-Vargas D, Caballero C et al. Inflammatory response in the hippocampus of PS1M146L/APP751SL mouse model of Alzheimer's disease: age-dependent switch in the microglial phenotype from alternative to classic. J Neurosci 2008; 28:11650-61.
93. Cardoso AL, Guedes JR, Pereira de Almeida L, Pedroso de Lima MC. miR-155 modulates microglia-mediated immune response by down-regulating SOCS-1 and promoting cytokine and nitric oxide production. Immunology 2012; 135:73-88.
94. Guedes J, Cardoso AL, Pedroso de Lima MC. Involvement of MicroRNA in microglia-mediated immune response. Clin Dev Immunol 2013; 2013:186872.
95. Yamamoto M, Kiyota T, Horiba M, Buescher JL, Walsh SM, Gendelman HE, Ikezu T. Interferon-γ and tumor necrosis factor-α regulate amyloid-β plaque deposition and β-secretase expression in Swedish mutant APP transgenic mice. Am J Pathol 2007; 170:680-92.
96. Ethell DW, Shippy D, Cao C, Cracchiolo JR, Runfeldt M, Blake B, Arendash GW. Aβ-specific T-cells reverse cognitive decline and synaptic loss in Alzheimer's mice. Neurobiol Dis 2006; 23:351-61.
97. Gallagher JJ, Finnegan ME, Grehan B, Dobson J, Collingwood JF, Lynch MA. Modest amyloid deposition is associated with iron dysregulation, microglial activation, and oxidative stress. J Alzheimers Dis 2012; 28:147-61.
98. Gallagher JJ, Minogue AM, Lynch MA. Impaired performance of female APP/PS1 Mice in the Morris water maze is coupled with increased Aβ accumulation and microglial activation. Neurodegener Dis 2013; 11:33-41.
99. Wilcock DM, Zhao Q, Morgan D, Gordon MN, Everhart A, Wilson JG, Lee JE, Colton CA. Diverse inflammatory responses in transgenic mouse models of Alzheimer's disease and the effect of immunotherapy on these responses. ASN Neuro 2011; 3:249-58.
100. Simard AR, Soulet D, Gowing G, Julien JP, Rivest S. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron 2006; 49:489-502.
101. Shechter R, Schwartz M. Harnessing monocyte-derived macrophages to control central nervous system pathologies: no longer 'if' but 'how'. J Pathol 2013; 229:332-46.
102. Chinetti-Gbaguidi G, Baron M, Bouhlel MA et al. Human atherosclerotic plaque alternative macrophages display low cholesterol handling but high phagocytosis because of distinct activities of the PPARγ and LXRα pathways. Circ Res 2011; 108:985-95.
103. Koenigsknecht-Talboo J, Landreth GE. Microglial phagocytosis induced by fibrillar β-amyloid and IgGs are differentially regulated by proinflammatory cytokines. J Neurosci 2005; 25:8240-9.
104. Fiala M, Lin J, Ringman J et al. Ineffective phagocytosis of amyloid-β by macrophages of Alzheimer's disease patients. J Alzheimers Dis 2005; 7:221-32. discussion 55-62.
105. Rao JS, Rapoport SI, Kim HW. Altered neuroinflammatory, arachidonic acid cascade and synaptic markers in postmortem Alzheimer's disease brain. Transl Psychiatry 2011; 1:e31.
106. Bhaskar K, Konerth M, Kokiko-Cochran ON, Cardona A, Ransohoff RM, Lamb BT. Regulation of tau pathology by the microglial fractalkine receptor. Neuron 2010; 68:19-31.
107. Lee DC, Rizer J, Selenica ML et al. LPS-induced inflammation exacerbates phospho-tau pathology in rTg4510 mice. J Neuroinflammation 2010; 7:56.
108. Downer EJ, Johnston DG, Lynch MA. Differential role of Dok1 and Dok2 in TLR2-induced inflammatory signaling in glia. Mol Cell Neurosci 2013; 56C:148-58.
109. Hickey WF. Migration of hematogenous cells through the blood-brain barrier and the initiation of CNS inflammation. Brain Pathol 1991; 1:97-105.
110. Hickey WF. Basic principles of immunological surveillance of the normal central nervous system. Glia 2001; 36:118-24.
111. Engelhardt B, Ransohoff RM. Capture, crawl, cross: the T cell code to breach the blood-brain barriers. Trends Immunol 2012; 33:579-89.
112. Fletcher JM, Lalor SJ, Sweeney CM, Tubridy N, Mills KH. T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin Exp Immunol 2010; 162:1-11.
113. Weissert R. The immune pathogenesis of multiple sclerosis. J Neuroimmune Pharmacol 2013; doi: 10.1007/s11481-013-9467-3.
114. + lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 2009; 119:182-92.
115. Rogers J, Luber-Narod J, Styren SD, Civin WH. Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer's disease. Neurobiol Aging 1988; 9:339-49.
116. Itagaki S, McGeer PL, Akiyama H. Presence of T-cytotoxic suppressor and leucocyte common antigen positive cells in Alzheimer's disease brain tissue. Neurosci Lett 1988; 91:259-64.
117. McGeer PL, Akiyama H, Itagaki S, McGeer EG. Immune system response in Alzheimer's disease. Can J Neurol Sci 1989; 16:516-27.
118. Hartwig M. Immune ageing and Alzheimer's disease. NeuroReport 1995; 6:1274-6.
119. Togo T, Akiyama H, Iseki E et al. Occurrence of T cells in the brain of Alzheimer's disease and other neurological diseases. J Neuroimmunol 2002; 124:83-92.
120. Town T, Tan J, Flavell RA, Mullan M. T-cells in Alzheimer's disease. Neuromolecular Med 2005; 7:255-64.
121. Pirttila T, Mattinen S, Frey H. The decrease of CD8-positive lymphocytes in Alzheimer's disease. J Neurol Sci 1992; 107:160-5.
122. Monsonego A, Zota V, Karni A et al. Increased T cell reactivity to amyloid β protein in older humans and patients with Alzheimer disease. J Clin Invest 2003; 112:415-22.
123. McManus R, Higgins S, Mills KHG, Lynch MA. Respiratory infection promotes T cell infiltration and amyloid-β deposition in APP/PS1 mice. Neurobiol Aging 2014; 35:109-21.
124. Murooka TT, Rahbar R, Platanias LC, Fish EN. CCL5-mediated T-cell chemotaxis involves the initiation of mRNA translation through mTOR/4E-BP1. Blood 2008; 111:4892-901.
125. + T cells in the lungs of patients with HIV infection and T-cell alveolitis. Am J Respir Crit Care Med 2000; 162:1466-73.
126. Schall TJ, Bacon K, Camp RD, Kaspari JW, Goeddel DV. Human macrophage inflammatory protein α (MIP-1α) and MIP-1β chemokines attract distinct populations of lymphocytes. J Exp Med 1993; 177:1821-6.
127. Tripathy D, Thirumangalakudi L, Grammas P. Expression of macrophage inflammatory protein 1α is elevated in Alzheimer's vessels and is regulated by oxidative stress. J Alzheimers Dis 2007; 11:447-55.
128. Tripathy D, Thirumangalakudi L, Grammas P. RANTES upregulation in the Alzheimer's disease brain: a possible neuroprotective role. Neurobiol Aging 2010; 31:8-16.
129. Xia MQ, Bacskai BJ, Knowles RB, Qin SX, Hyman BT. Expression of the chemokine receptor CXCR3 on neurons and the elevated expression of its ligand IP-10 in reactive astrocytes: in vitro ERK1/2 activation and role in Alzheimer's disease. J Neuroimmunol 2000; 108:227-35.
130. Man SM, Ma YR, Shang DS et al. Peripheral T cells overexpress MIP-1α to enhance its transendothelial migration in Alzheimer's disease. Neurobiol Aging 2007; 28:485-96.
131. Liu YJ, Guo DW, Tian L et al. Peripheral T cells derived from Alzheimer's disease patients overexpress CXCR2 contributing to its transendothelial migration, which is microglial TNF-α-dependent. Neurobiol Aging 2010; 31:175-88.
132. Reale M, Iarlori C, Feliciani C, Gambi D. Peripheral chemokine receptors, their ligands, cytokines and Alzheimer's disease. J Alzheimers Dis 2008; 14:147-59.
133. Ryu JK, McLarnon JG. A leaky blood-brain barrier, fibrinogen infiltration and microglial reactivity in inflamed Alzheimer's disease brain. J Cell Mol Med 2009; 13:2911-25.
134. Adams RA, Bauer J, Flick MJ, Sikorski SL, Nuriel T, Lassmann H, Degen JL, Akassoglou K. The fibrin-derived γ377-395 peptide inhibits microglia activation and suppresses relapsing paralysis in central nervous system autoimmune disease. J Exp Med 2007; 204:571-82.